A 56-year-old woman with a history of HIV on highly active antiretroviral therapy (HAART) with a history of anal and vulvar intraepithelial neoplasia presented to the colorectal clinic for evaluation of new perianal lesions. She had an undetectable viral load and CD4 + count of 181 and was compliant with HAART. On physical examination, she had white verrucous lesions, which appeared similar to her prior condylomata acuminata as well as a purple labial lesion. Excisional biopsies were obtained of these lesions. Biopsies of the anal condylomatous lesions were consistent with anal intraepithelial neoplasia (AIN)-1 and AIN-II as well as immunohistochemistry staining positive for ERG (ETS family transcription factor ERG), CD34, and human herpes virus-8 consistent with Kaposi sarcoma (KS). The left labial lesion was also consistent with KS (Fig. 1). A staging workup was performed, including a PET-CT scan, which showed widespread metabolic uptake in multiple lymph nodes throughout her body. The left axillary lymph nodes were biopsied and positive for KS. She was referred to medical oncology and was started on liposomal doxorubicin. She completed 6 cycles over 4 months. Posttreatment imaging showed a significant decrease in disease burden and lymphadenopathy. At 3 months posttreatment, the patient was seen in the clinic and noted to have recurrent perianal condylomatous lesions. Surgical excision of these lesions revealed AIN-3 and condylomata acuminata without any evidence of recurrent KS. At her 3-month surveillance visit, she had a recurrence of condylomatous lesions, which were surgically excised and revealed AIN-1. At subsequent visits over the following 2 years, she had no further evidence of KS lesions in the perianal area. Her labial lesion also regressed completely without any recurrence (Fig. 1).